General Information
Version
3
Revision date
2024-02-23
Product name
Domperidone
CAS No.
57808-66-9
Emergency telephone
001-800-227-6701, +32 14 57 52 11, 001-201-796-7100, +32 14 57 52 99, 001-800-424-9300, 001-703-527-3887
Icons in SDS
Company Information
company name
Avocado Research Chemicals Ltd
e-mail address of the competent person responsible for the Safety Data Sheet
begel.sdsdesk@thermofisher.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H361
Hazard statements
Code
Statements
H361
Suspected of damaging fertility or the unborn child
Section 2
SECTION 2: Hazards identification
CLP Classification - According to GB-CLP Regulations UK SI 2019/720 and UK SI 2020/1567 Classification of the substance or mixture
Physical hazards
Based on available data, the classification criteria are not met
Health hazards
Reproductive Toxicity Category 2 (H361) ______________________________________________________________________________________________ ALFAAJ63681 Page 1 / 10
Environmental hazards
Based on available data, the classification criteria are not met Full text of Hazard Statements: see section 16
Signal word
Warning
Hazard statements
H361 - Suspected of damaging fertility or the unborn child
Precautionary statements
P201 - Obtain special instructions before use P280 - Wear protective gloves/protective clothing/eye protection/face protection P308 + P313 - IF exposed or concerned: Get medical advice/attention
2.3 Other hazards
This product does not contain any known or suspected endocrine disruptors
2.1 Classification of the substance or mixture
CLP Classification - According to GB-CLP Regulations UK SI 2019/720 and UK SI 2020/1567 Physical hazards Based on available data, the classification criteria are not met Health hazards Reproductive Toxicity Category 2 (H361) ______________________________________________________________________________________________ ALFAAJ63681 Page 1 / 10 Environmental hazards Based on available data, the classification criteria are not met Full text of Hazard Statements: see section 16
